{"id":391673,"date":"2014-04-23T00:00:00","date_gmt":"2014-04-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/webgsp0814-biopharma-analyst-call-highlights-from-the-12th-ega-biosimilars-conference\/"},"modified":"2026-03-31T09:05:26","modified_gmt":"2026-03-31T09:05:26","slug":"webgsp0814-biopharma-analyst-call-highlights-from-the-12th-ega-biosimilars-conference","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/webgsp0814-biopharma-analyst-call-highlights-from-the-12th-ega-biosimilars-conference\/","title":{"rendered":"ANALYST CALL: Highlights from the 12th EGA Biosimilars Conference"},"content":{"rendered":"<p style=\"font: 12px\/14px arial; margin: 10px 20px 10px 15px; color: #333333; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;\"><strong><span style=\"color: red; font-family: 'Calibri','sans-serif'; font-size: 11pt; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"><strong><span style=\"color: red; font-family: 'Calibri','sans-serif'; font-size: 11pt; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">To view the recording from our webinar series, please select the video link to the left<\/span><\/strong><\/span><\/strong><\/p>\n<p style=\"font: 12px\/14px arial; margin: 10px 20px 10px 15px; color: #333333; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;\">\u00a0<\/p>\n<p><strong>Outline<\/strong><\/p>\n<p>&#8211; Background<\/p>\n<p>&#8211; Overarching theme of the EGA conference<\/p>\n<p>&#8211; Current and future startegies to drive biosimilar use in Europe<\/p>\n<p>&#8211; Roadmap for biosimilars policy outside of the major markets<\/p>\n<p>&#8211; Conclusions<\/p>\n<p>&#8211; Q&#038;A<\/p>\n","protected":false},"template":"","class_list":["post-391673","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-biosimilars","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":3,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391673\/revisions"}],"predecessor-version":[{"id":577036,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391673\/revisions\/577036"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}